Drug Approval | February 26, 2024
Concord Biotech receives GMP certificate from Kenya regulator
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
Sustainability is integral to Biocon's business purpose
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Subscribe To Our Newsletter & Stay Updated
